louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01531283: Deacylated Ghrelin and Beta Cell Function
Official title: Impact of Unacylated Ghrelin on Beta-cell Function in Humans
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: the Diabetic Process
Keywords: unacylated ghrelin
beta cell function
Lead sponsor: University of Cincinnati
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2012-02-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to examine the effect of physiologic levels of UAG on the regulation of glucose homeostasis as well as beta cell function.


Eligibility criteria: Inclusion Criteria:

1. Apparently healthy men and women. Only premenopausal women who are using an adequate method of contraception at Screening and who agree to continue the contraception during the study will be included. Male subjects do not need to use on birth control.
2. Ages between 18 and 50 years, inclusive.
3. BMI between 18.5 and 29.9 kg/m2, inclusive

Exclusion Criteria:

1. History or clinical evidence of impaired fasting glucose or impaired glucose tolerance or diabetes mellitus, myocardial infarction, history or symptoms of congestive heart failure, history of cancer or anorexia nervosa, history or active liver or renal disease (AST or ALT \>2x upper limits of normal, calculated glomerular filtration rate \[GFR\] \<60).
2. A baseline resting systolic blood pressure of less than 100 mm Hg.
3. History of growth hormone deficiency or excess disorders (acromegaly, pituitary gigantism, panhypopituitarism); history of adrenal insufficiency or Cushing's disease/syndrome; history of neuroendocrine tumors.
4. Anemia defined as hematocrit \<33%.
5. Use of medications that alter insulin sensitivity: niacin, glucocorticoids, metformin, thiazolidinediones, exenatide, or atypical anti-psychotics.
6. Pregnancy or lactation.
7. BMI \<18 kg/m2 or BMI \>30 kg/m2; fasting plasma glucose \>100 mg/dl and/or 2 hr plasma glucose \>140 mg/dl on a 75 g oral glucose tolerance test.
8. Electrocardiogram (ECG) abnormalities: specifically, myocardial ischemia, previous myocardial ischemia, atrial fibrillation, second or third degree heart block and complete right or left bundle branch block.
9. Females who are on progesterone-only contraception and those who have irregular menses.

Primary outcomes:
measure: acute insulin release (AIRg)
timeFrame: one year
Secondary outcomes:
measure: Insulin sensitivity
timeFrame: one year
measure: Disposition index
timeFrame: one year
measure: glucose tolerance
timeFrame: one year
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
Study officials:
References:
Clinical trial NCT05805683: Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Official title: Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Calcitonin
Neuropathic Pain
Spinal Cord Injury
Keywords: Calcitonin
Neuropathic pain
Spinal cord injury
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-04-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: PREVENTION

Brief summary: This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury

Detailed description: Pain after spinal cord injury can be classified into five categories: musculoskeletal, visceral, at-level, above-level, and below-level neuropathic pain. Calcitonin has previously been shown to be effective in the management of acute pain following amputation, vertebral fractures and other neuropathic conditions. Also it was used in a previous study to prevent complex regional pain syndrome in severe hemiplegic patients after stroke

Eligibility criteria: Inclusion Criteria:

* Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.

Exclusion Criteria:

* Intake of anticonvulsants medications.
* Evidence of neuropathic pain.
* Evidence of previous allergic reaction to calcitonin.
* Patients with renal, hepatic and cardiac dysfunction or neurological disorders .
* brain damage or major trauma to extremities or abdomen.

Primary outcomes:
measure: Intensity of neuropathic pain
timeFrame: 6 months after spinal cord injury
measure: Incidence of chronic pain
timeFrame: 12 months after spinal cord injury
Secondary outcomes:
measure: Incidence of neuropathic pain
timeFrame: 12 months after spinal cord injury
measure: The incidence of adverse reactions
timeFrame: 2 weeks after spinal cord injury
measure: The consumption of medications for neuropathic pain or musculoskeletal pain
timeFrame: 12 months after spinal cord injury
measure: Intensity of neuropathic pain
timeFrame: 12 months after spinal cord injury
measure: Intensity of nociceptive pain
timeFrame: 12 months after spinal cord injury
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: Gharbiya
Study officials:
References:
Clinical trial NCT01168583: Fluid Balance and Clinical Outcomes
Official title: Investigation of the Effect of Post-operative Fluid Balance on Inflammatory Mediators in Patients Undergoing Cardiovascular Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fluid Balance
Input and Output
Inflammatory Mediators
Acute Kidney Injury
Mortality
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2010-07-23
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to the hospital for elective cardiothoracic surgery.

Brief summary: This study is about investigating the relationship of postoperative fluid balance, inflammation and acute kidney injury. This is a non-interventional study (no drug administration). The investigators will collect baseline demographic data, postoperative fluid balance status by Intake-output data, follow routine labs and collect 1 blood sample (0.5ml) with morning lab draws on day 1 and 5ml urine samples on day 1 and 2.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older, and
* Undergoing elective cardiothoracic surgery(s), alone or in combination with other procedures/surgery(s): thoracic aortic aneurysm, cardiac valves, coronary artery bypass grafting, abdominal thoracic aneurysm, and other cardiovascular surgery.

Exclusion Criteria:

* Pregnancy
* History of any organ transplant
* Preoperative intra-aortic balloon pump (IABP)
* Current use of natriuretic peptides
* ESRD patients on dialysis
* Estimated GFR \< 30ml/min using MDRD equation.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Shands Hospital, University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: A Ahsan Ejaz, M.D
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Florida
name: Ganesh Kambhampati, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kambhampati G, Ejaz NI, Asmar A, Aiyer RK, Arif AA, Pourafshar N, Yalamanchili VR, Ejaz AA. Fluid balance and conventional and novel biomarkers of acute kidney injury in cardiovascular surgery. J Cardiovasc Surg (Torino). 2013 Oct;54(5):639-46.
citation: Ejaz AA, Kambhampati G, Ejaz NI, Dass B, Lapsia V, Arif AA, Asmar A, Shimada M, Alsabbagh MM, Aiyer R, Johnson RJ. Post-operative serum uric acid and acute kidney injury. J Nephrol. 2012 Jul-Aug;25(4):497-505. doi: 10.5301/jn.5000173.
citation: Kambhampati G, Ross EA, Alsabbagh MM, Asmar A, Pakkivenkata U, Ejaz NI, Arif AA, Ejaz AA. Perioperative fluid balance and acute kidney injury. Clin Exp Nephrol. 2012 Oct;16(5):730-8. doi: 10.1007/s10157-012-0623-5. Epub 2012 Mar 29.
Clinical trial NCT00214383: Internet Telehealth for Pediatric Asthma Case Management
Official title: Internet Telehealth for Pediatric Asthma Case Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Keywords: pediatric asthma
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2005-09-21
Enrollment: 301
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The original and primary aim of this study is to evaluate the effects of CHESS with Nurse Case Management on asthma control (symptom-free days), and adherence factors of children aged 4-12. The investigators have expanded the scope of the specific aims. The criteria for their expanded aim is to also interview low-income African-American caregivers to gain an understanding of how they conceptualize their child's asthma, and what they consider to be barriers or facilitators to managing their child's asthma. There is no change in the investigators' original aim.


Eligibility criteria: Inclusion Criteria:

* Parents of children, aged 4-12 with moderate to severe asthma

Primary outcomes:
measure: Percentage Changed in Adherence Score
timeFrame: Baseline compared to the mean of the combined 3, 6, 9, and 12 month scores
measure: Number of Symptom-free Days
timeFrame: Baseline compared to the mean of the combined 3, 6, 9, and 12 month scores
Secondary outcomes:
measure: Improvement in Asthma Control
timeFrame: Baseline compared to the mean of the combined 3, 6, 9, and 12 month scores
Other outcomes:
Locations:
Study officials:
affiliation: University of Wisconsin, Madison
name: David Gustafson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wise M, Gustafson DH, Sorkness CA, Molfenter T, Staresinic A, Meis T, Hawkins RP, Shanovich KK, Walker NP. Internet telehealth for pediatric asthma case management: integrating computerized and case manager features for tailoring a Web-based asthma education program. Health Promot Pract. 2007 Jul;8(3):282-91. doi: 10.1177/1524839906289983. Epub 2006 Aug 23.
citation: Wise M, Pulvermacher A, Shanovich KK, Gustafson DH, Sorkness C, Bhattacharya A. Using action research to implement an integrated pediatric asthma case management and eHealth intervention for low-income families. Health Promot Pract. 2010 Nov;11(6):798-806. doi: 10.1177/1524839909334621. Epub 2009 Jun 10.
citation: Gustafson D, Wise M, Bhattacharya A, Pulvermacher A, Shanovich K, Phillips B, Lehman E, Chinchilli V, Hawkins R, Kim JS. The effects of combining Web-based eHealth with telephone nurse case management for pediatric asthma control: a randomized controlled trial. J Med Internet Res. 2012 Jul 26;14(4):e101. doi: 10.2196/jmir.1964.
Clinical trial NCT00469183: Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
Official title: An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Melasma
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2007-05-04
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.

Detailed description: Same as above.

Eligibility criteria: Inclusion Criteria:

* Subjects must have a clinical diagnosis of moderate to severe melasma
* Subjects willing to undergo biopsy four times throughout the study, two biopsies at baseline (one in a melasma involved area and one in a non-involved area). The third and fourth biopsies will be performed at 3 months and 6 months, respectively; in order to avoid variability in histopathological findings,
* Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits.

Exclusion Criteria:

* Subjects with diagnosis of dermal melasma
* Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)
* Subjects who have used retinoids, steroids, and/or skin lightening products 4 weeks prior to study entry
* Subjects who show signs of Poikiloderma of Civatte (mandibular hyperpigmentation)
* Subjects with a history of hypertrophic scarring or a history of keloids
* Subjects who are unable to avoid the use of a class 1 steroid during their participation in the study

Primary outcomes:
measure: Safety - Skin biopsy evaluation - histological assessment of skin atrophy
timeFrame: Baseline, 12 weeks and 24 weeks
Secondary outcomes:
measure: Tolerability assessments; Incidence of adverse events; Global Assessment of Lesion Severity; MASI; Physician Global Assessment
timeFrame: Baseline, 12 weeks and 24 weeks
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Vitiligo and Pigmentation Institute of Southern California
state: California
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center of Dallas
state: Texas
Study officials:
affiliation: Galderma R&D
name: Ronald W Gottschalk, MD
role: STUDY_DIRECTOR
References:
citation: Grimes PE, Bhawan J, Guevara IL, Colon LE, Johnson LA, Gottschalk RW, Pandya AG. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010 Jun;62(6):962-7. doi: 10.1016/j.jaad.2009.06.067. Epub 2010 Apr 15.
Clinical trial NCT05392283: Vacuum Cupping for Chronic Neck and Back Pain
Official title: Vacuum Cupping for Chronic Neck and Back Pain - a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Neck Pain
Back Pain
Keywords: Vacuum cupping
Quantitative sensory testing
Lead sponsor: Jena University Hospital
Sponsor class: OTHER
Collaborators: name: University of Jena
name: Helheten Norway
name: National Research Centre of Complementary and Alternative Medicine, Norway
First posted: 2022-05-26
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Small clinical pilot studies have shown that vacuum massage-related techniques such as traditional dry cupping can reduce musculoskeletal pain such as back and neck pain. At the same time, little is yet known about the potential mechanisms of action of these therapies. A vacuum pump induces a massaging effect of the skin including the deeper tissue layers. The resulting massage technique corresponds to a kind of tissue manipulation similar to dry cupping. In this procedure, suction force and air flow can be individually adjusted. This is an advantage that can be used for patients with varying degrees of sensitivity or who are preloaded by patients with varying degrees of sensitivity or a history of pain. The aim of this study was to test the feasibility of the study design.


Eligibility criteria: Inclusion Criteria:

* chronic neck or back pain
* mean pain intensity ≥ 40 mm VAS

Exclusion Criteria:

* neurological symptoms or neuropathic pain
* vertebral column surgery less than 12 months prior to the study
* TENS, acupuncture, osteopathy, or a chiropractic maneuvre or infiltration at the area within 4 weeks prior to the inclusion in the study
* congenital deformation of the spine

Primary outcomes:
measure: Pain intensity (Numeric rating scale (NRS))
timeFrame: measured at baseline (week 1) and weekly during treatment (week 2 to 5) and 1 month after last treatment
Secondary outcomes:
measure: Quantitative sensory testing (QST)
timeFrame: measured at baseline (week 1) and weekly during treatment (week 2 to 5) and 1 month after last treatment
measure: Neck Disability Index (NDI)
timeFrame: measured at baseline (week 1), at the end of treatment (week 5) and after 1 month after last treatmentekly during treatment (week 2 to 5) and 1 month after last treatment
measure: Oswestry Disability Index (ODI)
timeFrame: measured at baseline (week 1), at the end of treatment (week 5) and after 1 month after last treatment
measure: Pain diary
timeFrame: filled in from baseline (week 1) until last treatment (week 5)
Other outcomes:
Locations:
city: Jena
country: Germany
facility: Jena University Hospital
Study officials:
References:
Clinical trial NCT05929183: Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent
Official title: Efficacy and Safety Study of Neuronavigation Occipital rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bipolar Disorder
Lead sponsor: First Affiliated Hospital of Zhejiang University
Sponsor class: OTHER
First posted: 2023-07-03
Enrollment: 40
Sex: ALL
Minimum age (years): 14
Maximum age (years): 28
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to explore a new stimulation target and protocol for the treatment of depressive episode in adolescents with bipolar disorder through the repetitive transcranial magnetic stimulation(rTMS) under neuronavigation, and verify whether there is abnormal functional connectivity between the emotion-related brain area orbital frontal lobe (OFC) and the primary visual cortex(V1) during the depressive episode, which will contribute to further understand the relevant neural pathway and mechanism.


Eligibility criteria: Inclusion Criteria:

1. Age 14-28 years old, regardless of gender;
2. Meet DSM-V diagnostic criteria for bipolar depressive episodes;
3. Young Mania Rating Scale (YMRS) ≤ 6 points;
4. MARDS:12-30 points.
5. Han nationality, right-handed;
6. More than 9 years of education.

Exclusion Criteria:

1. History of severe somatic or brain organic diseases and craniocerebral trauma;
2. Abnormal brain structure or any MRI contraindications were found by magnetic resonance examination;
3. Those who do not cooperate or cannot effectively complete the experiment;
4. Drug, alcohol or other psychoactive substance abusers;
5. Pregnant, lactating or planned pregnancy.
6. Severe suicidal ideation and behavior
7. ECT or rTMS treatment was performed within six months

Primary outcomes:
measure: Montgomery-Asberg Depression Rating Scale（MADRS）
timeFrame: 0-8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The First Affiliated Hospital of Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT02989883: Clinical Outcomes of Peroral Endoscopic Myotomy
Official title: Clinical Outcomes of Peroral Endoscopic Myotomy for Esophageal Outflow Obstruction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Achalasia
Keywords: achalasia
POEM
outcome
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2016-12-12
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Esophageal outflow obstruction is characterized by failure to relax the lower esophageal sphincter (LES), resulting in impaired flow of ingested food into the stomach. The subsequent stasis of ingested food leads to symptoms of dysphagia, regurgitation, chest pain, and weight loss. The core objective of the treatment of esophageal outflow obstruction is to disrupt the LES and reduce its pressure to allow esophageal emptying. Therapeutic options include pharmacologic therapy, Botulinum toxin injection, pneumatic balloon dilation, and surgical myotomy with partial fundoplication. In addition, peroral endoscopy myotomy (POEM) has recently been introduced as a minimally invasive treatment, but there have a few studies regarding long-term outcomes. The aim of this study is to evaluate clinical outcomes of POEM for esophageal outflow obstruction.

Detailed description: Prospective study

Eligibility criteria: Inclusion Criteria:

* Patients who were diagnosed as esophageal outflow obstruction
* Patients with informed consent

Exclusion Criteria:

* Diagnostic uncertainty
* Patients who are not suitable for general anesthesia

Primary outcomes:
measure: number of patients with Eckardt score <3 after the procedure
timeFrame: 1 month after the procedure
Secondary outcomes:
measure: adverse events which are related to the procedure
timeFrame: within 30 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Hwoon-Yong Jung
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gong EJ, Na HK, Ahn JY, Jung KW, Kim DH, Choi KD, Song HJ, Jung HY. Prospective evaluation of the efficacy of peroral endoscopic myotomy in patients with achalasia. Medicine (Baltimore). 2021 Jun 11;100(23):e26248. doi: 10.1097/MD.0000000000026248.
Clinical trial NCT00408083: Crossover Study With MultiHance vs a Comparator for Peripheral MRA
Official title: A Phase IIIB, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.1 Mmol/kg of Multihance With 0.1 Mmol/kg of Magnevist for Contrast-Enhanced Magnetic Resonance Angiography(CE-MRA) of Peripheral Arteries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Peripheral Vascular Disease
Lead sponsor: Bracco Diagnostics, Inc
Sponsor class: INDUSTRY
First posted: 2006-12-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This is a double blind crossover study designed to compare two different gadolinium products given at the same dose to patients undergoing MRA assessment of lower legs for the evaluation of peripheral steno-occlusive disease.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* At least 18 yrs of age
* Moderate to severe peripheral arterial disease
* Willing to undergo two MRA procedures within 14 days

Exclusion Criteria:

* Pregnant or lactating
* Known allergies to one or more ingredients in the products
* Therapeutic intervention in the arterial territory of interest between the two MRA exams
* Changes in symptoms between the two exams
* Vascular stent in area of interest
* Severe claustrophobia
* Congestive heart failure class IV
* Scheduled to undergo surgery for PAOD between the two exams
* Scheduled to undergo DSA between the two exams

Primary outcomes:
measure: Assessment of global paired diagnostic preference of the two MRA exams
timeFrame: Post dose
Secondary outcomes:
measure: To compare the two different products for signal intensity enhancement; average quality of visualization; technical failure rate; to assess inter-reader agreement in terms of average quality of visualization
timeFrame: post dose
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Bracco Imaging
Study officials:
affiliation: Bracco Diagnostics, Inc
name: Gianpaolo Pirovano, MD
role: STUDY_DIRECTOR
References: